Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone

Drug Development and Industrial Pharmacy

Volumn 39, Issue 1, 2013, Pages 39-50

  Aggarwal, Geeta ^a   Dhawan, Sanju ^b   Hari Kumar, S L ^a  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Bioavailability; Eudragit; Groundnut oil; Jojoba oil; Olive oil; Permeation; Pharmacokinetic

Indexed keywords

ARACHIS OIL; EUDRAGIT; OLIVE OIL; RISPERIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SCREENING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; RABBIT; RAT; ROTAROD TEST; SKIN IRRITATION; SKIN PENETRATION; TRANSDERMAL PATCH;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; MALE; MICE; OLEA; PERMEABILITY; PLANT OILS; POLYMETHACRYLIC ACIDS; RABBITS; RATS; RATS, WISTAR; RISPERIDONE; SKIN; TRANSDERMAL PATCH; WAXES;

EID: 84871228324     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.657643     Document Type: Article

References (40)

1. de Leon J, Diaz FJ. (2005). A meta-Analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res, 76:135-157. (Pubitemid 40812332)
2. Shore D. (1998). Recent developments in atypical antipsychotic medications. Schizophr Bull, 24:33. (Pubitemid 28128488)
3. Branford D. (2003). Schizophrenia. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics. 3rd ed. London: Churchill Livingstone, 459-460.
4. Newcomer JW. (2005). Second-Generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19 SUPPL1:1-93. (Pubitemid 40677047)
5. Aggarwal G, Dhawan S. (2009). Development, fabrication and evaluation of transdermal drug delivery system-A review. Latest Reviews [Online], 7(5). Available at www.pharmainfo.net. Assessed on 30 July 2011.
6. Nedberg DE, Gale RM, Crisologo NM, Wen J, Imbert EC, Luciano A, Silverberg EN, Foreman PB. (2007, March). Transdermal risperidone delivery system. WO/2007/035942.
7. Wertheimer AI, Santella TM, Finestone AJ, Levy RA. (2005). Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther, 22:559-577.
8. Sinha VR, Kaur MP. (2000). Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm, 26:1131-1140.
9. Charoo NA, Shamsher AA, Kohli K, Pillai K, Rahman Z. (2008). Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. Colloids Surf B Biointerfaces, 65:300-307.
10. Jain R, Aqil M, Ahad A, Ali A, Khar RK. (2008). Basil oil is a promising skin penetration enhancer for transdermal delivery of labetolol hydrochloride. Drug Dev Ind Pharm, 34:384-389. (Pubitemid 351519668)
11. Sharma S, Aggarwal G, Dhawan S. (2010). Design and evaluation of olanzapine transdermal patches containing vegetable oils as permeation enhancers. Der Pharmacia Lettre, 2(6):84-98.
12. Chandak AR, Verma PRP. (2010). Eudragit based transdermal delivery system of Pentazocin: Phycochemical, in vitro and in vivo evaluations. Pharm Dev Technol, 15:296-304.
13. Jayaprakash S, Halith SM, Firthouse PM, Yasmin, Nagarajan M. (2010). Preparation and evaluation of celecoxib transdermal patches. Pak J Pharm Sci, 23:279-283.
14. Yener G, Üner M, Gönüllü Ü, Yildirim S, Kiliç P, Aslan SS et al. (2010). Design of meloxicam and lornoxicam transdermal patches: Preparation, physical characterization, ex vivo and in vivo studies. Chem Pharm Bull, 58:1466-1473.
15. Mittal A, Parmar S, Singh B. (2009). In vitro and in vivo assessment of matrix type transdermal therapeutic system of labetalol hydrochloride. Curr Drug Deliv, 6:511-519.
16. El-Massik MA, Darwish IA, Hassan EE, El-Khordagui LK. (1996). Development of a dissolution medium for glibenclamide. Int J Pharm, 140:69-76. (Pubitemid 26276716)
17. Setty CM, Jawarkar Y, Pathan IB. (2010). Effect of essential oils as permeation enhancers on percutaneous penetration of furosemide through human cadaver skin. Acta Pharmaceut Sciencia, 52:159-168.
18. Chandak AR, Verma PR. (2008). [Design and development of hydroxypropyl methycellulose (HPMC) based polymeric films of methotrexate: Physicochemical and pharmacokinetic evaluations]. Yakugaku Zasshi, 128:1057-1066.
19. Zhang G, Terry AV Jr, Bartlett MG. (2007). Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci, 856:20-28. (Pubitemid 47302895)
20. Samanta MK, Dube R, Suresh B. (2003). Transdermal drug delivery system of haloperidol to overcome self-Induced extrapyramidal syndrome. Drug Dev Ind Pharm, 29:405-415. (Pubitemid 36528608)
21. Hai NT, Kim J, Park ES, Chi SC. (2008). Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm, 357:55-60.
22. Avenoso A, Facciolà G, Salemi M, Spina E. (2000). Determination of risperidone and its major metabolite 9-Hydroxyrisperidone in human plasma by reversed-Phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl, 746:173-181. (Pubitemid 30657933)
23. Chandra A, Sharma PK. (2009). Transdermal delivery of Ketorolac. Yakugaku Zasshi, 129(3):373-379.
24. Verma PR, Iyer SS. (2000). Transdermal delivery of propranolol using mixed grades of Eudragit: Design and in vitro and in vivo evaluation. Drug Dev Ind Pharm, 26:471-476. (Pubitemid 30207722)
25. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. (2007). Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech, 8:2.
26. Gullick DR, Pugh WJ, Ingram MJ, Cox PA, Moss GP. (2010). Formulation and characterization of a captopril ethyl ester drugin-Adhesive-Type patch for percutaneous absorption. Drug Dev Ind Pharm, 36:926-932.
27. Shamsher AA, Charoo NA, Kohli K, Pillai K, Rahman Z. (2010). Effect of transdermally delivered aspirin on blood coagulation parameters. Am J Biomed Sci, 2:129-141.
28. Aggarwal G, Dhawan S, Harikumar SL. (2011, Sep 14). Formulation, in vitro and in vivo evaluation of matrix type transdermal patches of Olanzapine. Pharm Dev Technol. [Epub ahead of print] DOI: 10.3109/10837450. 2011.609993
29. Karande P, Mitragotri S. (2009). Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophys Acta, 1788:2362-2373.
30. Li L, Fang L, Xu X, Liu Y, Sun Y, He Z. (2010). Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole. Biopharm Drug Dispos, 31:138-149.
31. Mukherjee B, Kanupriya, Mahapatra S, Das S, Patra B. (2005). Sorbitan monolaurate 20 as a potential skin permeation enhancer in transdermal patches. J Applied Research, 5:96-107.
32. Escobar-Chávez JJ, Merino V, Díez-Sales O, Nácher-Alonso A, Ganem-Quintanar A, Herráez M et al. (2011). Transdermal nortriptyline hydrocloride patch formulated within a chitosan matrix intended to be used for smoking cessation. Pharm Dev Technol, 16:162-169.
33. Charoo NA, Anwer A, Kohli K, Pillai KK, Rahman Z. (2005). Transdermal delivery of flurbiprofen: Permeation enhancement, design, pharmacokinetic, and pharmacodynamic studies in albino rats. Pharm Dev Technol, 10:343-351. (Pubitemid 41291471)
34. Aggarwal G, Garg A, Dhawan S. (2009). Transdermal drug delivery: Evolving technologies and expanding opportunities. Ind J Pharm Educ Res, 43(3):251-259.
35. Alam MI, Baboota S, Kohli K, Ali J, Ahuja A. (2009). Development and evaluation of transdermal patches of celecoxib. PDA J Pharm Sci Technol, 63:429-437.
36. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS, Jadhav UY. (2008). Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer. Int J Green Pharmacy, 2:129-133.
37. Jamieson GS, Baughman WF, Brauns DH. (1921). The chemical composition of peanut oil. J Am Chem Soc, 43:1372-1381.
38. Wang LH, Wang CC, Kuo SC. (2007). Vehicle and enhancer effects on human skin penetration of aminophylline from cream formulations: Evaluation in vivo. J Cosmet Sci, 58:245-254.
39. De P, Damodharan N, Mallick S, Mukherjee B. (2009). Development and evaluation of nefopam transdermal matrix patch system in human volunteers. PDA J Pharm Sci Technol, 63:537-546.
40. Ren C, Fang L, Ling L, Wang Q, Liu S, Zhao L et al. (2009). Design and in vivo evaluation of an indapamide transdermal patch. Int J Pharm, 370:129-135.